Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH9507 in HIV patients with excess abdominal fat
2006-005444-88Phase 3Completed
- Sponsor
- Theratechnologies Inc.
- Start
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HIV-associated lipodystrophy (HALS) and lipodystrophy comparing TH9507 2 mg with Placebo (2 arms). Primary endpoint: Percent change in visceral adipose tissue at week 26. Started Dec 2006; status: completed.
02
Drugs
tesamorelin
03
Conditions
HIV-associated lipodystrophy (HALS)lipodystrophy
Beyond the preview
Go deeper on 2006-005444-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005444-88.